Woodline Partners’s AnaptysBio ANAB Stock Holding History
Bought
Maintained
Sold
Other funds holding ANAB
EC
TCM
AAA
VCM
PAI
6CM
Woodline Partners's ANAB Position: Q1 2026 in Review
Woodline Partners reduced its AnaptysBio (ANAB) stake by 31% in Q1 2026, selling an estimated $8.43M and leaving 344,256 shares worth $19.1M. The position accounts for 0.07% of the portfolio, ranked #353.
Woodline Partners first reported a position in ANAB in Q1 2021 and has held it in 21 quarters since. The position peaked at $28.3M in Q3 2022. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.
- Woodline Partners held 344,256 shares of AnaptysBio worth $19.1M as of Q1 2026.
- Woodline Partners sold 156,767 AnaptysBio shares in Q1 2026, an estimated $8.43M.
- AnaptysBio made up 0.07% of Woodline Partners's portfolio in Q1 2026, its #353 holding.
- Woodline Partners first reported a position in AnaptysBio in Q1 2021 and has held it in 21 quarters since.
- Woodline Partners's AnaptysBio position peaked at $28.3M in Q3 2022.
- 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.
Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.